CP c.764A>T ;(p.E255V)

Variant ID: 3-148927015-T-A

NM_000096.3(CP):c.764A>T;(p.E255V)

This variant was identified in 56 publications

View GRCh38 version.




Publications:


Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience.

Frontiers In Oncology
Chitanava, Tamara T; Matvienko, Iuliia I; Shuvaev, Vasily V; Voloshin, Sergey S; Martynkevich, Irina I; Vlasova, Yulia Y; Efremova, Elizaveta E; Mileeva, Ekaterina E; Pirkhalo, Anna A; Makarova, Taiana T; Vlasik, Roman R; Karyagina, Elena E; Il Ina, Natalia N; Medvedeva, Nadezhda N; Dorofeeva, Natalia N; Shneider, Tatiana T; Siordiya, Nadia N; Kulemina, Olga O; Sbityakova, Evgenia E; Lazorko, Natalia N; Alexeeva, Julia J; Motorin, Dmitrii D; Morozova, Elena E; Lomaia, Elza E
Publication Date: 2023

Variant appearance in text: CP: E255V
PubMed Link: 37007128
Variant Present in the following documents:
  • Main text
  • fonc-13-1138683.pdf
View BVdb publication page



Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.

Scientific Reports
Sánchez, Ricardo R; Dorado, Sara S; Ruíz-Heredia, Yanira Y; Martín-Muñoz, Alejandro A; Rosa-Rosa, Juan Manuel JM; Ribera, Jordi J; García, Olga O; Jimenez-Ubieto, Ana A; Carreño-Tarragona, Gonzalo G; Linares, María M; Rufián, Laura L; Juárez, Alexandra A; Carrillo, Jaime J; Espino, María José MJ; Cáceres, Mercedes M; Expósito, Sara S; Cuevas, Beatriz B; Vanegas, Raúl R; Casado, Luis Felipe LF; Torrent, Anna A; Zamora, Lurdes L; Mercadal, Santiago S; Coll, Rosa R; Cervera, Marta M; Morgades, Mireia M; Hernández-Rivas, José Ángel JÁ; Bravo, Pilar P; Serí, Cristina C; Anguita, Eduardo E; Barragán, Eva E; Sargas, Claudia C; Ferrer-Marín, Francisca F; Sánchez-Calero, Jorge J; Sevilla, Julián J; Ruíz, Elena E; Villalón, Lucía L; Del Mar Herráez, María M; Riaza, Rosalía R; Magro, Elena E; Steegman, Juan Luis JL; Wang, Chongwu C; de Toledo, Paula P; García-Gutiérrez, Valentín V; Ayala, Rosa R; Ribera, Josep-Maria JM; Barrio, Santiago S; Martínez-López, Joaquín J
Publication Date: 2022-07-29

Variant appearance in text: CP: E255V
PubMed Link: 35906470
Variant Present in the following documents:
  • 41598_2022_17271_MOESM3_ESM.xlsx, sheet 1
View BVdb publication page



Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy.

Frontiers In Oncology
Andretta, Emanuela E; Costa, Caterina C; Longobardi, Consiglia C; Damiano, Sara S; Giordano, Antonio A; Pagnini, Francesco F; Montagnaro, Serena S; Quintiliani, Massimiliano M; Lauritano, Chiara C; Ciarcia, Roberto R
Publication Date: 2021

Variant appearance in text: CP: E255V
PubMed Link: 34993151
Variant Present in the following documents:
  • Main text
  • fonc-11-801779.pdf
View BVdb publication page



Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia.

Cancers
Ito, Kyoko K; Ito, Keisuke K
Publication Date: 2021-11-20

Variant appearance in text: CP: E255V
PubMed Link: 34830976
Variant Present in the following documents:
  • Main text
View BVdb publication page



Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools.

Targeted Oncology
Castagnetti, Fausto F; Binotto, Gianni G; Capodanno, Isabella I; Billio, Atto A; Calistri, Elisabetta E; Cavazzini, Francesco F; Crugnola, Monica M; Gozzini, Antonella A; Gugliotta, Gabriele G; Krampera, Mauro M; Lucchesi, Alessandro A; Merli, Anna A; Miggiano, Maria Cristina MC; Minotto, Claudia C; Poggiaspalla, Monica M; Salvucci, Marzia M; Scappini, Barbara B; Tiribelli, Mario M; Trabacchi, Elena E; Rosti, Gianantonio G; Galimberti, Sara S; Bonifacio, Massimiliano M
Publication Date: 2021-11

Variant appearance in text: CP: E255V
PubMed Link: 34661826
Variant Present in the following documents:
  • Main text
View BVdb publication page



Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining.

Frontiers In Oncology
Curik, Nikola N; Polivkova, Vaclava V; Burda, Pavel P; Koblihova, Jitka J; Laznicka, Adam A; Kalina, Tomas T; Kanderova, Veronika V; Brezinova, Jana J; Ransdorfova, Sarka S; Karasova, Dominika D; Rejlova, Katerina K; Bakardjieva, Marina M; Kuzilkova, Daniela D; Kundrat, David D; Linhartova, Jana J; Klamova, Hana H; Salek, Cyril C; Klener, Pavel P; Hrusak, Ondrej O; Machova Polakova, Katerina K
Publication Date: 2021

Variant appearance in text: CP: E255V
PubMed Link: 34616685
Variant Present in the following documents:
  • Main text
View BVdb publication page



Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature.

International Journal Of Hematology-Oncology And Stem Cell Research
Amouei, Asiyeh A; Daeian, Nesa N; Khezrnia, Seyedeh Sana SS; Mansouri, Ava A; Hadjibabaie, Molouk M
Publication Date: 2021-04-01

Variant appearance in text: CP: E255V
PubMed Link: 34466210
Variant Present in the following documents:
  • Main text
  • IJHOSCR-15-114.pdf
View BVdb publication page



Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.

International Journal Of Molecular Sciences
Yung, Yammy Y; Lee, Emily E; Chu, Hiu-Tung HT; Yip, Pui-Kwan PK; Gill, Harinder H
Publication Date: 2021-01-11

Variant appearance in text: CP: E255V
PubMed Link: 33440869
Variant Present in the following documents:
  • Main text
  • ijms-22-00659.pdf
View BVdb publication page



Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Asian Pacific Journal Of Cancer Prevention : Apjcp
Iqbal, Zafar Z; Absar, Muhammad M; Mahmood, Amer A; Aleem, Aamer A; Iqbal, Mudassar M; Jameel, Abid A; Akhtar, Tanveer T; Karim, Sajjad S; Rasool, Mahmood M; Mirza, Zeenat Z; Khalid, Muhammad M; Akram, Afia Muhammad AM; Sabar, Muhammad Farooq MF; Khalid, Ahmad M AM; Aljarrah, Khalid K; Iqbal, Janhangir J; Khalid, Muhammad M; Shah, Ijaz H IH; Alanazi, Nawaf N
Publication Date: 2020-12-01

Variant appearance in text: CP: E255V
PubMed Link: 33369447
Variant Present in the following documents:
  • Main text
  • APJCP-21-3517.pdf
View BVdb publication page



PVR and ICAM-1 on Blast Crisis CML Stem and Progenitor Cells with TKI Resistance Confer Susceptibility to NK Cells.

Cancers
Kim, Nayoung N; Kim, Mi-Yeon MY; Cho, Young-Uk YU; Chen, WenYong W; Lee, Kyoo-Hyung KH; Kim, Hun Sik HS
Publication Date: 2020-07-16

Variant appearance in text: CP: E255V
PubMed Link: 32708713
Variant Present in the following documents:
  • Main text
View BVdb publication page



Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.

Leukemia
Hochhaus, Andreas A; Gambacorti-Passerini, Carlo C; Abboud, Camille C; Gjertsen, Bjørn Tore BT; Brümmendorf, Tim H TH; Smith, B Douglas BD; Ernst, Thomas T; Giraldo-Castellano, Pilar P; Olsson-Strömberg, Ulla U; Saussele, Susanne S; Bardy-Bouxin, Nathalie N; Viqueira, Andrea A; Leip, Eric E; Russell-Smith, T Alexander TA; Leone, Jocelyn J; Rosti, Gianantonio G; Watts, Justin J; Giles, Francis J FJ; ,
Publication Date: 2020-08

Variant appearance in text: CP: E255V
PubMed Link: 32572189
Variant Present in the following documents:
  • Main text
  • 41375_2020_Article_915.pdf
  • 41375_2020_915_MOESM1_ESM.pdf
View BVdb publication page



Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors.

Leukemia
Hochhaus, Andreas A; Breccia, Massimo M; Saglio, Giuseppe G; García-Gutiérrez, Valentín V; Réa, Delphine D; Janssen, Jeroen J; Apperley, Jane J
Publication Date: 2020-06

Variant appearance in text: CP: E255V
PubMed Link: 32366938
Variant Present in the following documents:
  • Main text
  • 41375_2020_Article_842.pdf
View BVdb publication page



WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors

Turkish Journal Of Haematology : Official Journal Of Turkish Society Of Haematology
Haznedaroğlu, İbrahim C. İC; Kuzu, Işınsu I; İlhan, Osman O
Publication Date: 2020-02-20

Variant appearance in text: CP: E255V
PubMed Link: 31612694
Variant Present in the following documents:
  • TJH-37-42.pdf
View BVdb publication page



Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Blood
Hijiya, Nobuko N; Maschan, Alexey A; Rizzari, Carmelo C; Shimada, Hiroyuki H; Dufour, Carlo C; Goto, Hiroaki H; Kang, Hyoung Jin HJ; Guinipero, Terri T; Karakas, Zeynep Z; Bautista, Francisco F; Ducassou, Stéphane S; Yoo, Keon Hee KH; Zwaan, Christian Michel CM; Millot, Frédéric F; Aimone, Paola P; Allepuz, Alex A; Quenet, Sara S; Hourcade-Potelleret, Florence F; Hertle, Sabine S; Sosothikul, Darintr D
Publication Date: 2019-12-05

Variant appearance in text: CP: E255V
PubMed Link: 31511239
Variant Present in the following documents:
  • Main text
View BVdb publication page



Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients.

Scientific Reports
Chandrasekhar, Chodimella C; Kumar, Pasupuleti Santhosh PS; Sarma, Potukuchi Venkata Gurunadha Krishna PVGK
Publication Date: 2019-02-20

Variant appearance in text: CP: E255V
PubMed Link: 30787317
Variant Present in the following documents:
  • Main text
  • 41598_2019_Article_38672.pdf
View BVdb publication page



Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.

Haematologica
Gambacorti-Passerini, Carlo C; Cortes, Jorge E JE; Lipton, Jeff H JH; Kantarjian, Hagop M HM; Kim, Dong-Wook DW; Schafhausen, Philippe P; Crescenzo, Rocco R; Bardy-Bouxin, Nathalie N; Shapiro, Mark M; Noonan, Kay K; Leip, Eric E; DeAnnuntis, Liza L; Brümmendorf, Tim H TH; Khoury, H Jean HJ
Publication Date: 2018-08

Variant appearance in text: CP: E255V
PubMed Link: 29773593
Variant Present in the following documents:
  • 2017.171249.GAMBACORTI-PASSERINI_SUPPL.pdf
View BVdb publication page



Novel approaches to therapy in CML.

Hematology. American Society Of Hematology. Education Program
Bhatia, Ravi R
Publication Date: 2017-12-08

Variant appearance in text: CP: E255V
PubMed Link: 29222245
Variant Present in the following documents:
  • Main text
View BVdb publication page



Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.

Leukemia & Lymphoma
Boddu, Prajwal P; Shah, Abdul Rashid AR; Borthakur, Gautam G; Verstovsek, Srdan S; Garcia-Manero, Guillermo G; Daver, Naval N; Kadia, Tapan T; Ravandi, Farhad F; Jain, Nitin N; Alhuraiji, Ahmad A; Burger, Jan J; Kornblau, Steven S; Pierce, Sherry S; Dellasala, Sara S; Jabbour, Elias E; Kantarjian, Hagop H; Cortes, Jorge J
Publication Date: 2018-06

Variant appearance in text: CP: E255V
PubMed Link: 28972430
Variant Present in the following documents:
  • Main text
View BVdb publication page



Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.

Cancer
Jain, Preetesh P; Kantarjian, Hagop M HM; Ghorab, Ahmad A; Sasaki, Koji K; Jabbour, Elias J EJ; Nogueras Gonzalez, Graciela G; Kanagal-Shamanna, Rashmi R; Issa, Ghayas C GC; Garcia-Manero, Guillermo G; Kc, Devendra D; Dellasala, Sara S; Pierce, Sherry S; Konopleva, Marina M; Wierda, William G WG; Verstovsek, Srdan S; Daver, Naval G NG; Kadia, Tapan M TM; Borthakur, Gautam G; O'Brien, Susan S; Estrov, Zeev Z; Ravandi, Farhad F; Cortes, Jorge E JE
Publication Date: 2017-11-15

Variant appearance in text: CP: E255V
PubMed Link: 28743165
Variant Present in the following documents:
  • Main text
View BVdb publication page



Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.

Haematologica
Gleixner, Karoline V KV; Schneeweiss, Mathias M; Eisenwort, Gregor G; Berger, Daniela D; Herrmann, Harald H; Blatt, Katharina K; Greiner, Georg G; Byrgazov, Konstantin K; Hoermann, Gregor G; Konopleva, Marina M; Waliul, Islam I; Cumaraswamy, Abbarna A AA; Gunning, Patrick T PT; Maeda, Hiroshi H; Moriggl, Richard R; Deininger, Michael M; Lion, Thomas T; Andreeff, Michael M; Valent, Peter P
Publication Date: 2017-09

Variant appearance in text: CP: E255V
PubMed Link: 28596283
Variant Present in the following documents:
  • 2016.163436.GLEIXNER_SUPPL.pdf
View BVdb publication page



Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS).

Leukemia Research
Berman, Ellin E; Jhanwar, Suresh S; Hedvat, Cyrus C; Arcila, Maria E ME; Wahab, Omar Abdel- OA; Levine, Ross R; Maloy, Molly M; Ma, Wanlong W; Albitar, Maher M
Publication Date: 2016-10

Variant appearance in text: CP: E255V
PubMed Link: 27658269
Variant Present in the following documents:
  • Main text
View BVdb publication page



[Compliance to imatinib therapy in patients with chronic myeloid leukemia in Henan province and its influence on cytogenetic response at 12 months].

Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
Li, Z Z; Zhang, Yanli Y; Zhou, J J; Li, M J MJ; Wang, J J; Zhao, H F HF; Gui, R R RR; Zu, Y L YL; Song, Y P YP
Publication Date: 2016-07

Variant appearance in text: CP: E255V
PubMed Link: 27535858
Variant Present in the following documents:
  • cjh-37-07-581.pdf
View BVdb publication page



Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.

Blood Cancer Journal
Chen, Z Z; Wang, W W; Cortes, J E JE; Liu, E E; Miranda, R N RN; Zhao, C C; Yuan, J J; Lu, X X; Yang, W W; Ameri, M D MD; Kantarjian, H M HM; Medeiros, L J LJ; Hu, S S
Publication Date: 2016-05-06

Variant appearance in text: CP: E255V
PubMed Link: 27152845
Variant Present in the following documents:
  • bcj201627a.pdf
View BVdb publication page



[Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia].

Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
Jiang, Qian Q; Qin, Yazhen Y; Lai, Yueyun Y; Jiang, Hao H; Shi, Hongxia H
Publication Date: 2016-01

Variant appearance in text: CP: E255V
PubMed Link: 26876246
Variant Present in the following documents:
  • Main text
  • cjh-37-01-007.pdf
View BVdb publication page



Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.

Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research
Sadovnik, Irina I; Hoelbl-Kovacic, Andrea A; Herrmann, Harald H; Eisenwort, Gregor G; Cerny-Reiterer, Sabine S; Warsch, Wolfgang W; Hoermann, Gregor G; Greiner, Georg G; Blatt, Katharina K; Peter, Barbara B; Stefanzl, Gabriele G; Berger, Daniela D; Bilban, Martin M; Herndlhofer, Susanne S; Sill, Heinz H; Sperr, Wolfgang R WR; Streubel, Berthold B; Mannhalter, Christine C; Holyoake, Tessa L TL; Sexl, Veronika V; Valent, Peter P
Publication Date: 2016-04-15

Variant appearance in text: CP: E255V
PubMed Link: 26607600
Variant Present in the following documents:
  • Main text
View BVdb publication page



Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.

American Journal Of Hematology
Gambacorti-Passerini, Carlo C; Kantarjian, Hagop M HM; Kim, Dong-Wook DW; Khoury, Hanna J HJ; Turkina, Anna G AG; Brümmendorf, Tim H TH; Matczak, Ewa E; Bardy-Bouxin, Nathalie N; Shapiro, Mark M; Turnbull, Kathleen K; Leip, Eric E; Cortes, Jorge E JE
Publication Date: 2015-09

Variant appearance in text: CP: E255V
PubMed Link: 26040495
Variant Present in the following documents:
  • Main text
View BVdb publication page



Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.

Bmc Cancer
Cavelier, Lucia L; Ameur, Adam A; Häggqvist, Susana S; Höijer, Ida I; Cahill, Nicola N; Olsson-Strömberg, Ulla U; Hermanson, Monica M
Publication Date: 2015-02-12

Variant appearance in text: CP: E255V
PubMed Link: 25880391
Variant Present in the following documents:
  • Main text
View BVdb publication page



Drug Therapy in the Progressed CML Patient with multi-TKI Failure.

Mediterranean Journal Of Hematology And Infectious Diseases
Haznedaroglu, Ibrahim C IC
Publication Date: 2015

Variant appearance in text: CP: E255V
PubMed Link: 25745541
Variant Present in the following documents:
  • Main text
View BVdb publication page



Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor.

Plos One
Vaidya, Shantashri S; Vundinti, Babu Rao BR; Shanmukhaiah, Chandrakala C; Chakrabarti, Prantar P; Ghosh, Kanjaksha K
Publication Date: 2015

Variant appearance in text: CP: E255V
PubMed Link: 25629972
Variant Present in the following documents:
  • Main text
  • pone.0114828.pdf
View BVdb publication page



Resistant mutations in CML and Ph(+)ALL - role of ponatinib.

Biologics : Targets & Therapy
Miller, Geoffrey D GD; Bruno, Benjamin J BJ; Lim, Carol S CS
Publication Date: 2014

Variant appearance in text: CP: E255V
PubMed Link: 25349473
Variant Present in the following documents:
  • Main text
  • btt-8-243.pdf
View BVdb publication page



Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML).

Mediterranean Journal Of Hematology And Infectious Diseases
Haznedaroglu, Ibrahim C IC
Publication Date: 2014-01-01

Variant appearance in text: CP: E255V
PubMed Link: 24455118
Variant Present in the following documents:
  • Main text
View BVdb publication page



Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs.

Mediterranean Journal Of Hematology And Infectious Diseases
Breccia, Massimo M; Alimena, Giuliana G
Publication Date: 2014-01-02

Variant appearance in text: CP: E255V
PubMed Link: 24455112
Variant Present in the following documents:
  • Main text
View BVdb publication page



Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase.

Leukemia Research Reports
Bose, Prithviraj P; Park, Haeseong H; Al-Khafaji, Jawad J; Grant, Steven S
Publication Date: 2013-01-01

Variant appearance in text: CP: E255V
PubMed Link: 23977454
Variant Present in the following documents:
  • Main text
View BVdb publication page



The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis.

Haematologica
Nicolini, Franck E FE; Ibrahim, Amr R AR; Soverini, Simona S; Martinelli, Giovanni G; Müller, Martin C MC; Hochhaus, Andreas A; Dufva, Inge H IH; Kim, Dong-Wook DW; Cortes, Jorge J; Mauro, Michael J MJ; Chuah, Charles C; Labussière, Hélène H; Morisset, Stéphane S; Roche-Lestienne, Catherine C; Lippert, Eric E; Hayette, Sandrine S; Peter, Senaka S; Zhou, Wei W; Maguer-Satta, Véronique V; Michallet, Mauricette M; Goldman, John J; Apperley, Jane F JF; Mahon, François-Xavier FX; Marin, David D; Etienne, Gabriel G
Publication Date: 2013-10

Variant appearance in text: CP: E255V
PubMed Link: 23716543
Variant Present in the following documents:
  • Main text
View BVdb publication page



Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

Blood
Hochhaus, Andreas A; Saglio, Giuseppe G; Larson, Richard A RA; Kim, Dong-Wook DW; Etienne, Gabriel G; Rosti, Gianantonio G; De Souza, Carmino C; Kurokawa, Mineo M; Kalaycio, Matt E ME; Hoenekopp, Albert A; Fan, Xiaolin X; Shou, Yaping Y; Kantarjian, Hagop M HM; Hughes, Timothy P TP
Publication Date: 2013-05-02

Variant appearance in text: CP: E255V
PubMed Link: 23502220
Variant Present in the following documents:
  • Main text
View BVdb publication page



Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.

Plos One
Iqbal, Zafar Z; Aleem, Aamer A; Iqbal, Mudassar M; Naqvi, Mubashar Iqbal MI; Gill, Ammara A; Taj, Abid Sohail AS; Qayyum, Abdul A; ur-Rehman, Najeeb N; Khalid, Ahmad Mukhtar AM; Shah, Ijaz Hussain IH; Khalid, Muhammad M; Haq, Riazul R; Khan, Mahwish M; Baig, Shahid Mahmood SM; Jamil, Abid A; Abbas, Muhammad Naeem MN; Absar, Muhammad M; Mahmood, Amer A; Rasool, Mahmood M; Akhtar, Tanveer T
Publication Date: 2013

Variant appearance in text: CP: E255V
PubMed Link: 23409026
Variant Present in the following documents:
  • Main text
View BVdb publication page



BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.

Blood
Khorashad, Jamshid S JS; Kelley, Todd W TW; Szankasi, Philippe P; Mason, Clinton C CC; Soverini, Simona S; Adrian, Lauren T LT; Eide, Christopher A CA; Zabriskie, Matthew S MS; Lange, Thoralf T; Estrada, Johanna C JC; Pomicter, Anthony D AD; Eiring, Anna M AM; Kraft, Ira L IL; Anderson, David J DJ; Gu, Zhimin Z; Alikian, Mary M; Reid, Alistair G AG; Foroni, Letizia L; Marin, David D; Druker, Brian J BJ; O'Hare, Thomas T; Deininger, Michael W MW
Publication Date: 2013-01-17

Variant appearance in text: CP: E255V
PubMed Link: 23223358
Variant Present in the following documents:
  • Main text
View BVdb publication page



Treatments for chronic myeloid leukemia: a qualitative systematic review.

Journal Of Blood Medicine
Ferdinand, Roxanne R; Mitchell, Stephen A SA; Batson, Sarah S; Tumur, Indra I
Publication Date: 2012

Variant appearance in text: CP: E255V
PubMed Link: 22915985
Variant Present in the following documents:
  • Main text
  • jbm-3-051.pdf
View BVdb publication page



Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.

Haematologica
Russo Rossi, Antonella A; Breccia, Massimo M; Abruzzese, Elisabetta E; Castagnetti, Fausto F; Luciano, Luigiana L; Gozzini, Antonella A; Annunziata, Mario M; Martino, Bruno B; Stagno, Fabio F; Cavazzini, Francesco F; Tiribelli, Mario M; Visani, Giuseppe G; Pregno, Patrizia P; Musto, Pellegrino P; Fava, Carmen C; Sgherza, Nicola N; Albano, Francesco F; Rosti, Gianantonio G; Alimena, Giuliana G; Specchia, Giorgina G
Publication Date: 2013-03

Variant appearance in text: CP: E255V
PubMed Link: 22801965
Variant Present in the following documents:
  • Main text
View BVdb publication page



Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

Blood
Khoury, H Jean HJ; Cortes, Jorge E JE; Kantarjian, Hagop M HM; Gambacorti-Passerini, Carlo C; Baccarani, Michele M; Kim, Dong-Wook DW; Zaritskey, Andrey A; Countouriotis, Athena A; Besson, Nadine N; Leip, Eric E; Kelly, Virginia V; Brümmendorf, Tim H TH
Publication Date: 2012-04-12

Variant appearance in text: CP: E255V
PubMed Link: 22371878
Variant Present in the following documents:
  • Main text
View BVdb publication page



Molecular resistance: an early indicator for treatment change?

Clinical Lymphoma, Myeloma & Leukemia
Fava, Carmen C; Kantarjian, Hagop H; Cortes, Jorge J
Publication Date: 2012-04

Variant appearance in text: CP: E255V
PubMed Link: 22285607
Variant Present in the following documents:
  • Main text
View BVdb publication page



Evolution of therapies for chronic myelogenous leukemia.

Cancer Journal (Sudbury, Mass.)
Santos, Fabio P S FP; Kantarjian, Hagop H; Quintás-Cardama, Alfonso A; Cortes, Jorge J
Publication Date: 2011

Variant appearance in text: CP: E255V
PubMed Link: 22157290
Variant Present in the following documents:
  • Main text
View BVdb publication page



Chronic myeloid leukemia: mechanisms of resistance and treatment.

Hematology/Oncology Clinics Of North America
Jabbour, Elias E; Parikh, Sameer A SA; Kantarjian, Hagop H; Cortes, Jorge J
Publication Date: 2011-10

Variant appearance in text: CP: E255V
PubMed Link: 22054730
Variant Present in the following documents:
  • Main text
View BVdb publication page



Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line.

Journal Of Hematology & Oncology
Okabe, Seiichi S; Tauchi, Tetsuzo T; Tanaka, Yuko Y; Ohyashiki, Kazuma K
Publication Date: 2011-08-02

Variant appearance in text: CP: E255V
PubMed Link: 21806844
Variant Present in the following documents:
  • 1756-8722-4-32.pdf
View BVdb publication page



Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.

Blood
Jabbour, Elias E; Cortes, Jorge J; Santos, Fabio P S FP; Jones, Dan D; O'Brien, Susan S; Rondon, Gabriela G; Popat, Uday U; Giralt, Sergio S; Kebriaei, Partow P; Jones, Roy B RB; Kantarjian, Hagop H; Champlin, Richard R; de Lima, Marcos M
Publication Date: 2011-03-31

Variant appearance in text: CP: E255V
PubMed Link: 21156844
Variant Present in the following documents:
  • Main text
View BVdb publication page



Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib.

Oncotargets And Therapy
Breccia, Massimo M; Alimena, Giuliana G
Publication Date: 2008-10-01

Variant appearance in text: CP: E255V
PubMed Link: 21127752
Variant Present in the following documents:
  • Main text
View BVdb publication page



Optimizing combination therapies with existing and future CML drugs.

Plos One
Katouli, Allen A AA; Komarova, Natalia L NL
Publication Date: 2010-08-23

Variant appearance in text: CP: E255V
PubMed Link: 20808800
Variant Present in the following documents:
  • pone.0012300.pdf
View BVdb publication page



Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.

Clinical Therapeutics
Stein, Brady B; Smith, B Douglas BD
Publication Date: 2010-05

Variant appearance in text: CP: E255V
PubMed Link: 20685492
Variant Present in the following documents:
  • Main text
View BVdb publication page



Development and targeted use of nilotinib in chronic myeloid leukemia.

Drug Design, Development And Therapy
Fava, Carmen C; Kantarjian, Hagop H; Cortes, Jorge J; Jabbour, Elias E
Publication Date: 2009-02-06

Variant appearance in text: CP: E255V
PubMed Link: 19920910
Variant Present in the following documents:
  • Main text
View BVdb publication page



Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.

Blood
Nicolini, Franck E FE; Mauro, Michael J MJ; Martinelli, Giovanni G; Kim, Dong-Wook DW; Soverini, Simona S; Müller, Martin C MC; Hochhaus, Andreas A; Cortes, Jorge J; Chuah, Charles C; Dufva, Inge H IH; Apperley, Jane F JF; Yagasaki, Fumiharu F; Pearson, Jay D JD; Peter, Senaka S; Sanz Rodriguez, Cesar C; Preudhomme, Claude C; Giles, Francis F; Goldman, John M JM; Zhou, Wei W
Publication Date: 2009-12-17

Variant appearance in text: CP: E255V
PubMed Link: 19843886
Variant Present in the following documents:
  • Main text
View BVdb publication page



The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia.

Cancer Cell
Klemm, Lars L; Duy, Cihangir C; Iacobucci, Ilaria I; Kuchen, Stefan S; von Levetzow, Gregor G; Feldhahn, Niklas N; Henke, Nadine N; Li, Zhiyu Z; Hoffmann, Thomas K TK; Kim, Yong-mi YM; Hofmann, Wolf-Karsten WK; Jumaa, Hassan H; Groffen, John J; Heisterkamp, Nora N; Martinelli, Giovanni G; Lieber, Michael R MR; Casellas, Rafael R; Müschen, Markus M
Publication Date: 2009-09-08

Variant appearance in text: CP: E255V
PubMed Link: 19732723
Variant Present in the following documents:
  • Main text
View BVdb publication page



The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.

Blood
Garg, Ravin J RJ; Kantarjian, Hagop H; O'Brien, Susan S; Quintás-Cardama, Alfonso A; Faderl, Stefan S; Estrov, Zeev Z; Cortes, Jorge J
Publication Date: 2009-11-12

Variant appearance in text: CP: E255V
PubMed Link: 19729517
Variant Present in the following documents:
  • Main text
View BVdb publication page



High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.

Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology
Cortes, Jorge E JE; Kantarjian, Hagop M HM; Goldberg, Stuart L SL; Powell, Bayard L BL; Giles, Francis J FJ; Wetzler, Meir M; Akard, Luke L; Burke, John M JM; Kerr, Robert R; Saleh, Mansoor M; Salvado, August A; McDougall, Karen K; Albitar, Maher M; Radich, Jerald J; ,
Publication Date: 2009-10-01

Variant appearance in text: CP: E255V
PubMed Link: 19720924
Variant Present in the following documents:
  • Main text
View BVdb publication page



Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.

Biologics : Targets & Therapy
Valent, Peter P
Publication Date: 2007-12

Variant appearance in text: CP: E255V
PubMed Link: 19707313
Variant Present in the following documents:
  • Main text
View BVdb publication page



P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia.

Journal Of Hematology & Oncology
Cang, Shundong S; Liu, Delong D
Publication Date: 2008-10-01

Variant appearance in text: CP: E255V
PubMed Link: 18828913
Variant Present in the following documents:
  • Main text
  • 1756-8722-1-15.pdf
View BVdb publication page



Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.

Blood
Jabbour, Elias E; Kantarjian, Hagop H; Jones, Dan D; Breeden, Megan M; Garcia-Manero, Guillermo G; O'Brien, Susan S; Ravandi, Farhad F; Borthakur, Gautam G; Cortes, Jorge J
Publication Date: 2008-07-01

Variant appearance in text: CP: E255V
PubMed Link: 18403620
Variant Present in the following documents:
  • Main text
View BVdb publication page